vs

Side-by-side financial comparison of Versus Systems Inc. (VS) and Vivos Therapeutics, Inc. (VVOS). Click either name above to swap in a different company.

Vivos Therapeutics, Inc. is the larger business by last-quarter revenue ($3.8M vs $2.2M, roughly 1.8× Versus Systems Inc.). Versus Systems Inc. runs the higher net margin — -44.7% vs -180.3%, a 135.6% gap on every dollar of revenue.

Versus Systems Inc. operates a proprietary interactive reward platform that integrates with video games, streaming content, live sports broadcasts and mobile apps. It enables content creators and brands to offer personalized real-time prizes to audiences across North America and global digital entertainment markets.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

VS vs VVOS — Head-to-Head

Bigger by revenue
VVOS
VVOS
1.8× larger
VVOS
$3.8M
$2.2M
VS
Higher net margin
VS
VS
135.6% more per $
VS
-44.7%
-180.3%
VVOS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
VS
VS
VVOS
VVOS
Revenue
$2.2M
$3.8M
Net Profit
$-964.9K
$-6.9M
Gross Margin
0.2%
78.1%
Operating Margin
-54.2%
-166.8%
Net Margin
-44.7%
-180.3%
Revenue YoY
3.4%
Net Profit YoY
-19.2%
-143.8%
EPS (diluted)
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VS
VS
VVOS
VVOS
Q4 25
$2.2M
$3.8M
Q3 25
$0
$6.8M
Q2 25
$-176.0K
$3.8M
Q1 25
$3.0M
Q4 24
$0
$3.7M
Q3 24
$3.9M
Q2 24
$4.1M
Q1 24
$3.4M
Net Profit
VS
VS
VVOS
VVOS
Q4 25
$-964.9K
$-6.9M
Q3 25
$-537.8K
$-5.4M
Q2 25
$672.3K
$-5.0M
Q1 25
$-3.9M
Q4 24
$-809.5K
$-2.8M
Q3 24
$-2.6M
Q2 24
$-1.9M
Q1 24
$-3.8M
Gross Margin
VS
VS
VVOS
VVOS
Q4 25
0.2%
78.1%
Q3 25
58.0%
Q2 25
55.2%
Q1 25
50.0%
Q4 24
56.7%
Q3 24
60.5%
Q2 24
65.4%
Q1 24
56.7%
Operating Margin
VS
VS
VVOS
VVOS
Q4 25
-54.2%
-166.8%
Q3 25
-69.8%
Q2 25
-127.4%
Q1 25
-129.9%
Q4 24
-75.9%
Q3 24
-68.5%
Q2 24
-47.8%
Q1 24
-110.7%
Net Margin
VS
VS
VVOS
VVOS
Q4 25
-44.7%
-180.3%
Q3 25
-79.6%
Q2 25
-382.0%
-131.2%
Q1 25
-128.1%
Q4 24
-76.4%
Q3 24
-67.8%
Q2 24
-47.6%
Q1 24
-110.1%
EPS (diluted)
VS
VS
VVOS
VVOS
Q4 25
$-0.58
Q3 25
$-0.49
Q2 25
$0.14
$-0.55
Q1 25
$-0.45
Q4 24
$-0.27
$0.41
Q3 24
$-0.40
Q2 24
$-0.60
Q1 24
$-1.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VS
VS
VVOS
VVOS
Cash + ST InvestmentsLiquidity on hand
$527.4K
$2.0M
Total DebtLower is stronger
$2.9M
Stockholders' EquityBook value
$10.2M
$-1.5M
Total Assets
$2.1M
$25.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VS
VS
VVOS
VVOS
Q4 25
$527.4K
$2.0M
Q3 25
$3.1M
Q2 25
$4.4M
Q1 25
$2.3M
Q4 24
$3.1M
$6.3M
Q3 24
$6.3M
Q2 24
$6.9M
Q1 24
$2.6M
Total Debt
VS
VS
VVOS
VVOS
Q4 25
$2.9M
Q3 25
Q2 25
Q1 25
Q4 24
$1.2M
Q3 24
$1.2M
Q2 24
$1.2M
Q1 24
Stockholders' Equity
VS
VS
VVOS
VVOS
Q4 25
$10.2M
$-1.5M
Q3 25
$11.1M
$2.5M
Q2 25
$11.7M
$4.6M
Q1 25
$4.4M
Q4 24
$11.4M
$8.0M
Q3 24
$7.7M
Q2 24
$6.3M
Q1 24
$582.0K
Total Assets
VS
VS
VVOS
VVOS
Q4 25
$2.1M
$25.2M
Q3 25
$3.1M
$25.6M
Q2 25
$3.8M
$26.0M
Q1 25
$11.3M
Q4 24
$3.5M
$15.3M
Q3 24
$15.3M
Q2 24
$15.8M
Q1 24
$11.8M
Debt / Equity
VS
VS
VVOS
VVOS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
0.16×
Q2 24
0.19×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VS
VS
VVOS
VVOS
Operating Cash FlowLast quarter
$-568.6K
$-3.8M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-139.7%
Capex IntensityCapex / Revenue
40.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VS
VS
VVOS
VVOS
Q4 25
$-568.6K
$-3.8M
Q3 25
$24.7K
$-4.2M
Q2 25
$-867.5K
$-3.5M
Q1 25
$-3.8M
Q4 24
$-716.6K
$-2.9M
Q3 24
$-4.2M
Q2 24
$-3.0M
Q1 24
$-2.5M
Free Cash Flow
VS
VS
VVOS
VVOS
Q4 25
$-5.3M
Q3 25
$-4.2M
Q2 25
$-4.3M
Q1 25
$-3.9M
Q4 24
$-3.1M
Q3 24
$-4.4M
Q2 24
$-3.1M
Q1 24
$-2.7M
FCF Margin
VS
VS
VVOS
VVOS
Q4 25
-139.7%
Q3 25
-62.6%
Q2 25
-111.6%
Q1 25
-129.9%
Q4 24
-84.0%
Q3 24
-113.4%
Q2 24
-76.7%
Q1 24
-78.0%
Capex Intensity
VS
VS
VVOS
VVOS
Q4 25
40.0%
Q3 25
1.2%
Q2 25
20.2%
Q1 25
4.0%
Q4 24
4.5%
Q3 24
5.0%
Q2 24
1.5%
Q1 24
4.4%
Cash Conversion
VS
VS
VVOS
VVOS
Q4 25
Q3 25
Q2 25
-1.29×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

VS
VS

Segment breakdown not available.

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

Related Comparisons